Investor Alert

New York Markets Open in:

Market Pulse Archives

Oct. 11, 2021, 8:12 a.m. EDT

Protagonist Therapeutics shares soar after FDA lifts clinical hold on its experimental cancer drug

Watchlist Relevance

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Protagonist Therapeutics Inc. (PTGX)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Jaimy Lee

Shares of Protagonist Therapeutics Inc. /zigman2/quotes/205674595/composite PTGX -0.18% soared 87.0% in premarket trading on Monday after the company said the Food and Drug Administration had lifted a clinical hold on clinical trials of rusfertide, its experimental blood cancer treatment. The hold was put into place over concerns of skin tumors from animal research and a deeper examination of four new cancer cases that emerged during a clinical trial. No safety concerns were identified during the hold. The investigational treatment is expected to move forward into a Phase 3 clinical trial for polycythemia vera in the first quarter of next year. SVB Leerink analyst Joseph Schwartz told investors that lifting the clinical hold is a "very welcomed surprise, given the hold was disclosed less than a month ago, and it was unclear how long it would last." Protagonist's stock is down 9.5% so far this year, while the broader S&P 500 /zigman2/quotes/210599714/realtime SPX +1.30% is up 16.9%.

US : U.S.: Nasdaq
$ 22.74
-0.04 -0.18%
Volume: 1.02M
March 21, 2023 4:00p
P/E Ratio
Dividend Yield
Market Cap
$1.17 billion
Rev. per Employee
+51.30 +1.30%
Volume: 0.00
March 21, 2023 5:04p

This Story has 0 Comments
Be the first to comment
More News In

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.